Potentials of Fractionated Infusions of Low-dose Peripheral Blood Stem Cells (PBSCs) to Overcome the Hematologic Toxocities after Combination Chemotherapy.
- Author:
Seok Goo CHO
1
;
Jun Mo LEE
;
Jin No PARK
;
Hoon Kyo KIM
;
Sung Eun NAMKOONG
;
Kyung Shick LEE
;
Chun Choo KIM
Author Information
1. Catholic Hematopoietic Stem Cell Transplantation Center, Departments of College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Peripheral blood stem cell;
Hematologic toxicities;
Thrombocytopenia
- MeSH:
Appointments and Schedules;
Blood Platelets;
Drug Therapy;
Drug Therapy, Combination*;
Granulocyte-Macrophage Progenitor Cells;
Humans;
Leukopenia;
Lymphoma;
Stem Cells*;
Thrombocytopenia
- From:Journal of the Korean Cancer Association
2000;32(5):943-953
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We tried to evaluate the clinical usefullness of fractionated low-dose infusions of peripheral blood stem cells (PBSCs) as a supportive care. MATERIALS AND METHODS: Four patients were entered onto this study who were diagnosed to have gastric lymphoma (n=1) and advanced ovarian carcinomas (n=3). To overcome the hematologic toxicities, G-CSF-mobilized PBSCs were collected early in disease course. Harvested products were cryopreserved in aliquotes and then infused after each cycle. Planned therapeutic schedules should be performed without changes of dose and interval regardless of hematologic toxicities. RESULTS: 20 cycles of chemotherapies were performed and data of infused cell doses were as follows: median number of PBSCs infusions, 4.5 (3~5); median MNCs, CFU-GM colony counts per infusion of low-dose PBSCs, 1.7 108/kg (1.0~2.4), 3.2 104/kg (2.1~11.8). Among 20 cycles, delayed recovery of thrombocytopenia was shown on 10 cycles. Leukopenia (III/IV) and thrombocytopenia (III/IV) were shown on 8/6 cycles and 8/2 cycles. In spite of myelosuppression, they were successfully treated with planned dose-intensity. Especially incomplete platelet recovery was successfully rescuced by using fractionated infusions of low-dose PBSCs. CONCLUSION: These data warrant further clinical trials to evaluate the potentials of fractionated low-dose infusions of PBSCs collected early in disease course for overcoming accumulated hematologic toxicities, especially thrombocytopenia complicated by repeated chemotherapies.
